Tumour models London 1-3 December 2015 Agenda

Christian Gerdes
Head of Pharmacology,
Roche Pharma Research & Early
Development
Roche Innovation Center Zürich
17 Expert Speakers Include:
Jürgen Moll
Director Pharmacology &
Translational Research
Boehringer-Ingelheim
Sukhvinder Sidhu
Head of Pharmacology, Oncology Drug
Discovery & Preclinical Development
Sanofi
Giovanni Di Veroli
Associate Director of Systems
Pharmacology
AstraZeneca
Marie Dutreix
Director of Research
Institut Curie
Harness the Latest Humanized, Syngeneic, PDX & Ex Vivo Models to:
• Enhance Validation & Lead Optimisation of Discoveries
• Improve Preclinical Predictions & Translational Decisions
• Ensure Clinical Success & Enhanced Patient Outcomes
1-3 December 2015 LONDON, UK
Lead Partner: Additional Partners:
Tel: +44 (0)20 3141 8700 | Email: info@hansonwade.com
www.tumour-models.com RESEARCHED &
DEVELOPED BY:
Tumor Models @Tumor_Models
Book now and save up to £500
4th Annual

Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
www.tumour-models.com Tumor Models @Tumor_Models
Tumour Models London | 1-3 December 2015, London, UK
Welcome Back to Tumour Models London 2015
Tumour Models London 2015, now in its 4th year,is
the leading meeting dedicated to improve preclinical
predictability and translational success of oncology
discoveries. Tackling clinical failures rates, preclinical
strategies and translational challenges, this Summit
will enable you to translate your discoveries from model to
human studies with superior predictability to future proof
clinical success.
With the explosion of cancer immunotherapies and
combination therapies, the 4th Tumour Models London
Summit will bring together scientific leaders from
pharma, biotech and academia, who will equip you to
advance therapies through innovative in vitro, in vivo and
ex vivo models. Discover the innovative ways the industry
is developing humanized mice and the preclinical data
being generated to advance immunotherapies across the
translational gap.
With the field poised for success, optimise your preclinical
strategies to accelerate your understanding of your drug
candidates by making faster strategic decisions. Tumour
Models London will detail the latest work and case studies
from those striving to create a step-change in improving
preclinical predictability and translational success.
2. Learn how ex vivo models are being utilised
to mimic the tumour microenvironment
2.Discover how the industry are developing
humanized mice models for routine use in
preclinical trials
5 Key Benefits to Takeaway
1.Discover how syngeneic models are
optimising preclinical predictions for the
development cancer immunotherapies
1.Enhance your current preclinical strategies to
better predict the clinical outcomes of your
drug candidates
3.Uncover and interpret early clinical data to
better understand the preclinical predictions
generated from PDX models
3.Harness the immuno-competent models
being applied for the development of cancer
immunotherapies
4.Discover the strategies being applied to
develop combination therapies to overcome
resistance mechanisms
4.Capture how PDX models are optimising
preclinical predictions through reverse-
translation
5.Understand the latest developments in
optimising metastasis models to capture the
heterogeneous patient population
5.Optimise your data interpretation from
preclinical studies to enhance the clinical
success of your drug candidates
5 Key Ideas to Implement
Increase Speed and Efficiency of Progressing Your Most Promising Drug
Candidates Across the Translational Gap

Speakers
SEARCH GROUPS FOR:
Tumor Models London 2015
to join the online community.
Andrew McKenzie
Director, Scientific Operations
Michael Lisanti
Director, Breast Cancer Now
Research Unit, Institute of
Cancer Sciences
Giovanni Di Veroli
Associate Director of Systems
Pharmacology
Marie Dutreix
Director of Research
Kelli Ryan
Senior Scientist
Julie Stock
Preclinical RaDCom
Project Manager
Neal Goodwin
VP, Corporate Research
Development
Adam O’Shea
Scientist
Sophia Karagiannis
Senior Lecturer in Translational
Cancer Immunology, Head of
Cancer Antibody Discovery
Immunotherapy
Brian Soper
Technical Information
Scientist
Bruno Gomes
Senior Project Leader
Society
Anne Chessex
Senior Scientific Officer,
Pharmacology Screening
Christian Gerdes
Roche Pharma Research
Early Development
Jürgen Moll,
Director Pharmacology
Translational Research
Sukhvinder Sidhu
Oncology Drug Discovery
Preclinical Development
Christoph Schatz
Senior Scientist
Mustafa Djamgoz
Professor of Cancer Biology
Excellent conference, very good balance of presentation between suppliers,
academics, large pharma and biotech. The quality of talks was good and the
informal networking was very useful
Past Tumour Models London attendee, e-Therapeutics plc

Workshop A
This interactive workshop will give you the chance to learn from a highly
experienced senior scientist and other leading researchers within the field of cancer
immunotherapy and the current developments of immuno-competent models.
Key takeaway and questions to be addressed include:
• Exploring the different strategies of immune system humanization in mice
• How predictive are the humanized mouse models (predictive validity, efficacy/
safety/biomarkers)?
• Exploring humanized models to select combinations of immunotherapies
• Discussing the further improvements required and how other models could
support them
Bruno Gomes has more than ten years of experience in pharmaceutical companies as a in
vivo study director in oncology, head of in vivo oncology, and finally a senior project leader in
immunotherapies. He has developed strong expertise in oncology, immunology and the drug
development process, leading preclinical programs with kinase inhibitors and onco-immunology
drugs. He has been focusing on increasing the translational relevance of preclinical models
(including syngeneic tumour models in mice, xenografts and PDX tumour models in mice,
humanized mice models and spontaneous canine tumours).
Workshop leader
Bruno Gomes
Senior Project Leader Society
iTeos Therapeutics
Is Using Mice in an Humanized Immune System Really Improving the Clinical Translation
of New Immunotherapies?
Tuesday 1st December 2015 | Time: 9.00-12.00
A structured networking session
- run like speed dating- especially
designed to facilitate quick
introductions to the majority of
attendees within the preclinical
oncology field. Use the time
wisely to meet new contacts,
reconnect with old friends and
identify those you want to spend
more time with.
Take part in facilitated discussion
sessions focused around
specific, high priority issues
surrounding preclinical models.
Discuss your experiences and
observations within focus groups
then share your and the other
groups’ findings with the main
conference.
In between the formal
presentations the networking
carries on. Use the multiple
refreshment and lunch breaks
to continue your discussions in
an informal relaxed atmosphere.
Move from scientific discoveries
into meaningful collaborations.
Speed
Networking
Round Table
Discussions
Structured
Networking Breaks
Networking at Tumour Models London 2015

08.00 Registration Breakfast
09.00 Chairman’s Opening Remarks
Mustafa Djamgoz, Professor of
Cancer Biology, Imperial College
London
Preclinical Modelling to Elevate All Discoveries
9.10 Identifying Responsive Patient Populations in the Preclinic: Adopting
Clinically-Relevant Models Across Oncology Therapeutics
• Developing CDX and PDX modelling for breast and prostate cancer for enhanced
translational success
• How to satisfy the demand for clinically relevant models for understanding
disease progression
Andrew McKenzie, Director,
Scientific Operations, Crown
Bioscience
9.40 Predictive Value of Preclinical In Vitro and In Vivo Models
• Hear examples of predictability of cell based and in vivo models
• Learn about the current limitations and pitfalls using CDX, PDX and syngeneic in
vivo models
• Discover how organoids are an emerging technology at the transition of cell based
and in vivo models
Jürgen Moll, Director
Pharmacology Translational
Research, Boehringer-Ingelheim
10.10 Morning Refreshments Speed Networking
Modelling the Next Wave of Immunotherapies
11.10 Modelling Efficacy of Cancer Immunotherapies
• Clinical entrance de-risking strategies for immunotherapy platforms
• Discuss lessons learnt from modelling antibody dependent cell cytotoxicity
immunotherapies
• How to develop preclinical strategies to further enhance the development of
immunotherapies
Christian Gerdes, Head of
Pharmacology, Roche
Pharma Research Early
Development , Roche Innovation
Center Zürich
11.40 Humanized NSGTM Mice for Evaluation of Immuno-Oncology
Therapeutics
• Learn how the use of NSGTM mouse, JAX® In Vivo Pharmacology Services has
combined the human CD34+ hematopoietic stem cell engrafted NSG with human
patient derived xenograft to create a platform for humanized preclinical studies in
immuno-oncology
• Find out how this platform has been used to evaluate immune checkpoint inhibitors
such as Keytruda
• Address how we are evaluating NSG-SGM3 mice for humanization and co-
engraftment of PDX, as these mice express human IL-3, GM-CSF, and KIT ligand,
that allow improved development of regulatory T cells and myeloid cells
• Discover how several PDX tumours have been successfully engrafted in the hu-
CD34 NSG-SGM3 hosts, enabling further research into both the basic biology and
development of therapeutics in human immuno-oncology
Brian Soper, Technical
Information Scientist, The Jackson
Laboratory
12.10 Immunologically-Relevant Tumour Models to Interrogate Antibody
Efficacy and to Bridge the Translational Gap
• Interrogating direct mechanisms of action and effector functions and efficacy of
anti-tumour antibodies by employing a combination of tailored in vitro and in vivo
evaluations
• Design of cancer models relevant to antibody biology, human immunity and human
malignant disease to interrogate antibody efficacy and safety
• Translating antibodies of different classes/subclasses through interrogating
humanized, PDX and surrogate in vivo models
Sophia Karagiannis, Senior
Lecturer in Translational
Cancer Immunology, Head of
Cancer Antibody Discovery
Immunotherapy, King’s College
London
Conference Day One
Wednesday 2nd December 2015

4.40 Chair’s Closing Remarks
Mustafa Djamgoz, Professor of Cancer
Biology, Imperial College London
5.00 Drinks Reception Hosted by Crown Bioscience
Maximise the use of in
vivo and in vitro models to
better predict drug-related
toxicities at the preclinical
stage, detect adverse events
and avoid costly mistakes in
the clinic
4.
12.40 Networking Lunch
Microenvironment Combination Cancer Therapies
1.40 Combinations of Targeted Therapies with Radiotherapy: The Dbait
Repair Inhibitors to Fight Resistance
• Challenges of pre-clinic studies with radiotherapy: The need of dedicated platforms
• Safety issues: Planned combinations versus incidental associations
• Discover how to address radiosensitizers
• The repair inhibitor Dbait: Using an agonist to disable all DNA repair pathways
• From bench-to-bedside. What did we learn?
Marie Dutreix, Director of
Research, Institut Curie
2.10 Driving Early Phase Combinations in the UK
• The Combinations Alliance is a joint initiative between the Cancer Research UK
Centre for Drug Development (CDD), the Experimental Cancer Medicines Centre
network (ECMC) and industry collaborators
• Identify and deliver the best early phase combination trials to maximise treatment
options for people with cancer by driving forward industry and academia
collaborations
• Learn about how these collaborations will bring together strengths from both fields,
in particular using the academic expertise to ensure the correct animal models are
used for preclinical work
• Explore the CRUK funding available to build preclinical evidence to support
the progression of novel drug combinations into early phase trials, including
radiotherapy-drug combinations
Julie Stock, Preclinical RaDCom
Project Manager,
Cancer Research UK
2.40 Targeting Tumour Metabolism to Eradicate Cancer Stem Cells:
In Vitro and In Vivo Models of Tumourigenesis
• Disease models and target biology: How to relate cancer biology to
preclinical models
• How can we truly understand the metastatic microenvironment?
• Discuss models that accurately recapitulate human tumour biology at the level of
morphology, heterogeneity and genomics
Michael Lisanti, Director,
Breast Cancer Now Research
Unit, Institute of Cancer
Sciences, University of
Manchester
3.10 Afternoon Refreshments Poster Session
3.40 Breakout Roundtables: Bridging the Gap Between Discovery and the Clinic
Improving the understanding of
your immunotherapies: Lessons
learned and data generated from
syngeneic models, humanized
models and ex vivo approaches
Sukhvinder Sidhu,
Head of Pharmacology, Oncology
Drug Discovery Preclinical
Development, Sanofi
1.
Preclinical Phase
II Trials - How
to effectively run
coupled/co-clinical
trials?
2.
Advancing tumour models that
physiologically represent the
tumour microenvironment to
enhance prediction of patient
clinical outcomes
Breast Cancer Now Research
Unit, Institute of Cancer
Sciences, University of
Manchester
3.

08.00 Registration Breakfast
09.00 Chairman’s Opening Remarks
London
Translational Research: Personalised Models for Personalised Medicines
9.10 Selecting Preclinical Models for Immunotherapy
• Immunotherapy is an emerging field in oncology and different preclinical systems
are required compared to tumour therapies
• Refine in vivo model selection more effectively by following comprehensive profiling
of the model
• Understand the immune context of the tumour allows response hypotheses to be
built based on immunological criteria
• Link mouse model data to human clinical sample analysis to allow hypotheses to be
further refined to guide translational and clinical strategy
Kelli Ryan, Senior Scientist,
MedImmune
9.40 PDX-Directed Programs for Clinical Advancement
• A PDX platform where patient tumours are engrafted to form models for predictive
personalised treatment testing
• Address the therapeutic treatment responses in the PDX being used prospectively to
guide patient treatment and responses
• Learn to design downstream predictive treatment algorithms using biomarker data
analysed to ascertain signatures of molecular response
• PDX resources for conducting efficient high-throughput translational medicine
screens across multitudes of models
Neal Goodwin, VP, Corporate
Research Development,
Champions Oncology
10.10 Drug Repurposing for the Development of Novel Cancer Therapies
• Characterisation of novel mechanisms operating in cancer to form the bases of
targeted therapies which, in part, can be made possible by ‘repurposing’ drugs from
other fields of medicine
• Targeting metastasis with anti-epileptic and anti-anginal drugs, which have been
shown to be anti-invasive in vivo
London
10.40 Morning Refreshments
Optimal Predictors of Clinical Outcomes
11.10 Naturally Occurring Canine Cancer as a Translational Model for Novel
Anti-Cancer Therapies
• What comparative oncology tells us about the interests of spontaneous canine
tumours as models for cancer research
• An example of clinical pharmacology study in naturally occurring canine lymphoma
• How this model could be useful for translational studies of new immunotherapies
Bruno Gomes, Senior Project
Leader, Society,
iTeos Therapeutics
11.40 Use of Patient-Derived Material in Translational Research to
Support Drug Development in Oncology
Highlighting the following:
• In vitro tumour colony formation assays using PDX for indication screening
• Ex vivo explants from fresh tumour biopsies to investigate drug combinations
• In vivo mouse trials: Study design, data interpretation and translation to the clinics
Anne Chessex, Senior Scientific
Officer, Pharmacology
Screening, Debiopharm
Conference Day Two
Thursday 3rd December 2015

12.10 Identification of Potential Biomarkers to Predict Therapeutic Efficacy
to Drive Preclinical to Clinical Translation
• Preclinical identification of predictive biomarkers for cancer treatment
• Learn to identify biomarkers for patient stratification and molecular signatures of
drug response
• Use PDX models as predictive tools to prepare clinical trials
Christoph Schatz, Senior Scientist,
Bayer Healthcare
1.10 Networking Lunch
2.10 Development of Preclinical Models in Radioimmunotherapy
• Radioimmunoconjugate therapy: Working with radioactivity in preclinical
cancer models
• Highlighting specific problems with using immune compromised mice for
radioimmunotherapy studies
• How to measure toxicity and efficacy of radioimmunotherapy in mouse models?
Adam O’Shea, Scientist, Nordic
Nanovector ASA
2.40 The Analysis of Drug Combinations in Tumour Models
• Identify combination benefits through mathematical modelling
• Use mathematical models of synergy to develop potential combination therapies
• Evaluate the combinations’ toxicity vs. efficacy to improve clinical outcomes
Giovanni Di Veroli, Associate
Director of Systems
Pharmacology, AstraZeneca
3.10 Afternoon Refreshments
Novel Models to Accurately Guide Next Generation Cancer Therapies
3.40 Panel Discussion: Highlight Cutting Edge Advances in In Vivo, In Vitro
and In Silico Modelling to Facilitate a Discussion About Effective
Translational Approaches in Cancer Research
• Can preclinical models predict the results of phase 3 clinical trials?
• What toolkit of models does a preclinical research need to harness, when should
they use them and when should they invest?
• Best practice for implementing novel strategies of preclinical cancer research
• Innovative in vitro models for minimising preclinical mistakes and ultimately
clinical failures
• How to effectively evaluate novel cancer therapeutics as well as to identify
predictive biomarkers in early stages of drug development
Moderator: Mustafa Djamgoz,
Professor of Cancer Biology,
Imperial College London
Sukhvinder Sidhu, Head of
Pharmacology, Oncology
Drug Discovery Preclinical
Development, Sanofi
Manchester Breakthrough Breast
Cancer Research Unit, University
of Manchester
4.10 Chairman’s Closing Remarks
London
4.15 Close of Tumour Models London 2015
Outstanding meeting with first class speakers. I learned a lot and I will certainly
recommend the meeting to my colleagues
Past Tumour Models London attendee, Sanofi Aventis

Partners
Crown Bioscience
Crown Bioscience provides Translational Platforms focused
on fast-tracking candidates to identify biomarkers and patient
responders based on the pharmacological response of human
surrogate models. Power your Drug Discovery using the
world’s largest commercial collection of well-characterised
PDX in passage (HuPrime) plus a curated, searchable
database of patient, genotypic and phenotypic data as well
as pharmacological response (HuBase). Identify potential
biomarkers (HuSignature™) based on pharmacological
response or use your biomarker signature to identify models
available for screening to confirm patient responder and non-
responder populations (HuTrials™). Fast forward your drug
discovery programs today.
www.crownbio.com
Champions Oncology
Champions Oncology was founded by renowned
specialists in the field of cancer diagnosis, treatment, and
research. The Champions Oncology team is comprised of
seasoned oncology professionals passionately dedicated
to working to accelerate oncology drug development,
improve treatment outcomes and extend lives. Our core
platform, the Champions TumorGraft™ offers an enhanced
xenograft mouse avatar model for growing and testing
human tumours. Champions Personalized TumorGrafts™
empower patients and physicians using an in vivo xenograft
mouse avatar based diagnostic model that has shown
to be predictive of a patients’ clinical response to cancer
treatments and anticancer therapies.
www.championsoncology.com
The Jackson Laboratory
The Jackson Laboratory is an independent, nonprofit
biomedical research institution and a National Cancer
Institute-designated Cancer Center. Founded in 1929, the
Laboratory applies its eight decades of expertise in genetics
to increase understanding of human disease, advancing
treatments and cures for cancer, neurological and immune
disorders, diabetes, aging and heart disease. It models and
interprets genomic complexity, integrates basic research
with clinical application, educates current and future
scientists, and empowers the global biomedical community
by providing critical data, tools and services.
www.jax.org
Harlan Laboratories
Harlan Laboratories is a leading global provider of research
models and services to the worldwide Pharmaceutical,
Biotech, Contract Research and Academic/Government
sectors. Global availability of high quality nude mice, SCID
mice, nude rats and general purpose models for your area
of oncology research with proven performance in tumour
update and growth.
www.harlan.com
Tumour Models London 2015 is proud to partner with the following industry pioneers:
Lead Partner Program Partner
Program Partner Exhibitor
Become a Tumour Models Commercial Partner
Diane McKenna
Commercial Director
Tel: +44 (0)203 141 8700
Email: sponsor@hansonwade.com

Code:5156
* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require payment at time of registration and on or before the
cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include
travel or hotel accommodation.
Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees
will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same
organisation can be made at any time.
Changes to Conference Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or
damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God,
natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may
be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor
Gardens, London, SW1W 0AU
Hanson Wade Limited. Registered in England Wales. Company No: 6752216
Terms Conditions
Register
Event Prices
Pricing Venue
Hilton London Olympia Hotel
380 Kensington High St,
London W14 8NL
Accommodation: Overnight
accommodation is not included in the
registration fee, however accommodation
options will be sent out with your
confirmation email upon registering.
www.tumour-models.com/register
Tel: +44 (0)203 141 8700
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only valid
when three or more delegates from one
company book and pay at the same time.
Team Discounts*
Industry Pricing
Package
Register Pay before
9th October 2015
Register Pay before
6th November 2015
Standard Prices
Conference + Workshop £2098 + VAT (save £500) £2298 + VAT (save £300) £2498 + VAT (save £100)
Conference Only £1599 + VAT (save £400) £1799 + VAT (save £200) £1999 + VAT
Workshop Only £599 + VAT
Academic Not-For-Profit Pricing
Package
Register Pay before
9th October 2015
Register Pay before
6th November 2015
Standard Prices
Conference + Workshop £1258.80 + VAT £1378.80 + VAT £1498.90 + VAT
Conference Only £959.40 + VAT £1079.40 + VAT £1498.90 + VAT
Workshop Only £359.40 + VAT
Full payment is due on registration.
VAT is charged at 20%

Tumour models London 1-3 December 2015 Agenda

Recomendados

Recomendados

Mais conteúdo relacionado

Mais procurados

Mais procurados (10)

Destaque

Destaque (15)

Semelhante a Tumour models London 1-3 December 2015 Agenda

Semelhante a Tumour models London 1-3 December 2015 Agenda (20)

Mais de Diane McKenna

Mais de Diane McKenna (11)

Último

Último (20)

Tumour models London 1-3 December 2015 Agenda